Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level Bio ABFRA:4MB 23 Return-on-Tangible-Asset is -5.37% as of Mar. 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 71.83% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Level Bio AB's annualizedNet Income for the quarter that ended in Mar. 2026 was €-0.06 Mil. Level Bio AB's average total tangible assets for the quarter that ended in Mar. 2026 was €1.19 Mil. Therefore, Level Bio AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -5.37%.
The historical rank and industry rank for Level Bio AB's Return-on-Tangible-Asset or its related term are showing as below:
FRA:4MB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -60.21 Med: -10.27 Max: 31.59
Current: -24.05
During the past 13 years, Level Bio AB's highest Return-on-Tangible-Asset was 31.59%. The lowest was -60.21%. And the median was -10.27%.
FRA:4MB's Return-on-Tangible-Asset is ranked worse than 71.83% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs FRA:4MB: -24.05
Level Bio AB (FRA:4MB) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Level Bio AB Return-on-Tangible-Asset Related Terms
Level Bio AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Level Bio AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4MB vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Level Bio AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Level Bio AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -5.37% mean?
Level Bio AB (FRA:4MB) has a Return-on-Tangible-Asset of -5.37% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Level Bio AB and its competitors. According to the industry distribution chart, Level Bio AB ranks #153 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 71.8%.
Is Level Bio AB's Return-on-Tangible-Asset too high?
Level Bio AB's current Return-on-Tangible-Asset is -5.37%. Based on the distribution chart, Level Bio AB ranks #153 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #153 out of 213 companies for Return-on-Tangible-Asset. This places Level Bio AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Level Bio AB and its competitors. Level Bio AB's current Return-on-Tangible-Asset is -5.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Return-on-Tangible-Asset of -5.37%. The current Return-on-Tangible-Asset is -5.37%. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Return-on-Tangible-Asset is -5.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
